tiprankstipranks
Advertisement
Advertisement

MTVA Stock Latest News

Analyst Maintains Buy on MetaVia, Keeps $8 Price Target as DA-1726 Next-Gen Obesity Data Advances
RatingsAnalyst Maintains Buy on MetaVia, Keeps $8 Price Target as DA-1726 Next-Gen Obesity Data Advances
16h ago
MTVA
Analyst Reaffirms Buy on MTVA as DA-1726 Data De-Risk Obesity and MASH Opportunity; Price Target Maintained at $20
PremiumRatings
Analyst Reaffirms Buy on MTVA as DA-1726 Data De-Risk Obesity and MASH Opportunity; Price Target Maintained at $20
20h ago
MTVA
MetaVia Advances DA-1726 Obesity Trial to Top Doses
PremiumCompany Announcements
MetaVia Advances DA-1726 Obesity Trial to Top Doses
2d ago
8K
MTVA
MetaVia announces completion of dose titration in Phase 1 study of DA-1726
PremiumThe Fly
MetaVia announces completion of dose titration in Phase 1 study of DA-1726
2d ago
MTVA
MetaVia Announces $4 Million At-The-Market Stock Offering
PremiumCompany Announcements
MetaVia Announces $4 Million At-The-Market Stock Offering
8d ago
8K
MTVA
MetaVia: Buy Rating Reiterated as Synergistic Cardiometabolic Pipeline Supports Unchanged $8 Price Target
PremiumRatingsMetaVia: Buy Rating Reiterated as Synergistic Cardiometabolic Pipeline Supports Unchanged $8 Price Target
28d ago
MTVA
MetaVia Shareholders Approve Equity Plan and Reverse Split
Premium
Company Announcements
MetaVia Shareholders Approve Equity Plan and Reverse Split
1M ago
8K
MTVA
MetaVia highlights obesity and metabolic pipeline advancements
Premium
Company Announcements
MetaVia highlights obesity and metabolic pipeline advancements
1M ago
8K
MTVA
MetaVia presents data at ADA supporting DA-1726, vanoglipel
PremiumThe Fly
MetaVia presents data at ADA supporting DA-1726, vanoglipel
1M ago
MTVA
Fein Reiterates Buy on MetaVia as New Phase 1 Liver Data De-Risk DA-1726 and Support Unchanged $20 Price Target
PremiumRatings
Fein Reiterates Buy on MetaVia as New Phase 1 Liver Data De-Risk DA-1726 and Support Unchanged $20 Price Target
1M ago
MTVA
MetaVia’s DA-1726 shows efficacy in obesity and MASH presentations
PremiumThe Fly
MetaVia’s DA-1726 shows efficacy in obesity and MASH presentations
1M ago
MTVA
MetaVia highlights promising Phase 1 obesity drug data
PremiumCompany Announcements
MetaVia highlights promising Phase 1 obesity drug data
1M ago
8K
MTVA
3 Penny Stocks to Watch Now, 5/21/26
PremiumMarket News3 Penny Stocks to Watch Now, 5/21/26
2M ago
HCWB
MTVA
Analyst Reiterates Buy on MetaVia, Maintains $8 Price Target Amid Promising Metabolic Pipeline and Upcoming Data Catalysts
Premium
Ratings
Analyst Reiterates Buy on MetaVia, Maintains $8 Price Target Amid Promising Metabolic Pipeline and Upcoming Data Catalysts
2M ago
MTVA
Fein Reiterates Buy on MetaVia, Keeps DA-1726-Driven Price Target Unchanged at $20
Premium
Ratings
Fein Reiterates Buy on MetaVia, Keeps DA-1726-Driven Price Target Unchanged at $20
2M ago
MTVA
MetaVia Showcases Key Cardiometabolic Data at ADA 2026
PremiumCompany Announcements
MetaVia Showcases Key Cardiometabolic Data at ADA 2026
2M ago
8K
MTVA
MetaVia Highlights Strong DA-1726 Phase 1 Weight-Loss Data
PremiumCompany Announcements
MetaVia Highlights Strong DA-1726 Phase 1 Weight-Loss Data
2M ago
8K
MTVA
MetaVia to Present New DA-1726 Obesity Data at EASL
PremiumCompany Announcements
MetaVia to Present New DA-1726 Obesity Data at EASL
2M ago
8K
MTVA
MetaVia Advances DA-1726 Obesity Trial With First Patient
PremiumCompany Announcements
MetaVia Advances DA-1726 Obesity Trial With First Patient
3M ago
8K
MTVA
MetaVia says first patient dosed in Part 3 of Phase 1 trial of DA-1726
PremiumThe FlyMetaVia says first patient dosed in Part 3 of Phase 1 trial of DA-1726
3M ago
MTVA
MetaVia (MTVA): Differentiated Dual-Agonist Obesity Therapy and Solid Cash Runway Underpin Buy Rating
Premium
Ratings
MetaVia (MTVA): Differentiated Dual-Agonist Obesity Therapy and Solid Cash Runway Underpin Buy Rating
3M ago
MTVA
Maintaining Buy on MetaVia: Advancing DA-1726 Clinical Profile and Differentiated Obesity/MASH Strategy Despite Reduced Target Price
Premium
Ratings
Maintaining Buy on MetaVia: Advancing DA-1726 Clinical Profile and Differentiated Obesity/MASH Strategy Despite Reduced Target Price
4M ago
MTVA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >